MA27154A1 - Derives de quinazoline pour le traitement d'une croissance cellulaire anormale - Google Patents

Derives de quinazoline pour le traitement d'une croissance cellulaire anormale

Info

Publication number
MA27154A1
MA27154A1 MA27731A MA27731A MA27154A1 MA 27154 A1 MA27154 A1 MA 27154A1 MA 27731 A MA27731 A MA 27731A MA 27731 A MA27731 A MA 27731A MA 27154 A1 MA27154 A1 MA 27154A1
Authority
MA
Morocco
Prior art keywords
treatment
cell growth
abnormal cell
quinazoline derivatives
present
Prior art date
Application number
MA27731A
Other languages
English (en)
Inventor
John Charles Kath
Richard Damian Connell
James Dale Moyer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27154A1 publication Critical patent/MA27154A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 12 Décembre 2001 60/341,091 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de quinazoline pour le traitement d'une croissance cellulaire anormale La présente invention concerne des dérivés de quinazoline qui sont utiles dans le traitement d'une croissance cellulaire anormale, telle qu'un cancer, chez des mammifères. La présente invention concerne également une méthode d'utilisation de telles petites molécules dans le traitement d'une croissance anormale chez des mammifères, notamment chez l'homme, et des compositions pharmaceutiques contenant ces composés. La présente invention concerne en outre de petites molécules qui sont sélectives pour le récepteur erbB2 par rapport au récepteur erbB1, ledit inhibiteur de erbB2 ayant une gamme de sélectivités pour erbB2 par rapport au erbB1 de 50 à 1500.
MA27731A 2001-12-12 2004-06-08 Derives de quinazoline pour le traitement d'une croissance cellulaire anormale MA27154A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
MA27154A1 true MA27154A1 (fr) 2005-01-03

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27731A MA27154A1 (fr) 2001-12-12 2004-06-08 Derives de quinazoline pour le traitement d'une croissance cellulaire anormale

Country Status (29)

Country Link
US (1) US20030171386A1 (fr)
EP (1) EP1465632A1 (fr)
JP (1) JP4181502B2 (fr)
KR (1) KR20040063948A (fr)
CN (1) CN1602195A (fr)
AP (1) AP2004003058A0 (fr)
AR (1) AR037771A1 (fr)
AU (1) AU2002339687A1 (fr)
BR (1) BR0214499A (fr)
CA (1) CA2469670A1 (fr)
DO (1) DOP2002000545A (fr)
EA (1) EA200400680A1 (fr)
EC (1) ECSP045146A (fr)
GT (1) GT200200273A (fr)
HR (1) HRP20040529A2 (fr)
HU (1) HUP0501069A2 (fr)
IL (1) IL161908A0 (fr)
IS (1) IS7233A (fr)
MA (1) MA27154A1 (fr)
MX (1) MXPA04004107A (fr)
NO (1) NO20042882L (fr)
OA (1) OA12734A (fr)
PA (1) PA8561301A1 (fr)
PE (1) PE20030760A1 (fr)
PL (1) PL373848A1 (fr)
TN (1) TNSN04111A1 (fr)
TW (1) TW200301121A (fr)
WO (1) WO2003049740A1 (fr)
ZA (1) ZA200404264B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
BR0317433A (pt) * 2002-12-18 2005-11-16 Pfizer Prod Inc Derivados bicìclicos para o tratamento do crescimento celular anormal
JP2006512355A (ja) * 2002-12-19 2006-04-13 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−｛４−［３−メチル−４−（６−メチルピリジン−３−イルオキシ）−フェニルアミノ］−キナゾリン−６−イル｝−アリル）−アセトアミドの複合体、それらの製造方法および使用
BRPI0413745A (pt) * 2003-08-18 2006-10-24 Pfizer Prod Inc horário mde dosagem para agentes anticancerìgenos erbb2
EP2612853A1 (fr) * 2003-09-26 2013-07-10 Exelixis Inc. Modulateurs c-Met et produits d'utilisation
CN1921864A (zh) * 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
EP1896451A2 (fr) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Derives bicycliques pour le traitement de croissance cellulaire anormale
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2009098061A1 (fr) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour les produire
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
RU2614254C2 (ru) 2011-08-31 2017-03-24 Дженентек, Инк. Диагностические маркеры
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2017003668A1 (fr) 2015-07-01 2017-01-05 California Institute Of Technology Systèmes d'administration à base de polymère d'acide mucique cationique
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
JP2023512174A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP2023512175A (ja) * 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1192151B1 (fr) * 1999-07-09 2007-11-07 Glaxo Group Limited Anilino-quinazolines comme inhibiteurs de la proteine tyrosine kinase
AU778588B2 (en) * 1999-10-19 2004-12-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EE200200710A (et) * 2000-06-22 2004-06-15 Pfizer Products Inc. Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production

Also Published As

Publication number Publication date
EP1465632A1 (fr) 2004-10-13
PA8561301A1 (es) 2003-12-30
JP2005527486A (ja) 2005-09-15
BR0214499A (pt) 2005-05-10
IL161908A0 (en) 2005-11-20
CN1602195A (zh) 2005-03-30
PE20030760A1 (es) 2003-09-05
GT200200273A (es) 2003-10-03
OA12734A (en) 2006-06-28
HRP20040529A2 (en) 2004-10-31
ZA200404264B (en) 2005-08-31
US20030171386A1 (en) 2003-09-11
ECSP045146A (es) 2004-07-23
EA200400680A1 (ru) 2005-06-30
DOP2002000545A (es) 2003-06-16
NO20042882L (no) 2004-07-07
AU2002339687A1 (en) 2003-06-23
IS7233A (is) 2004-04-26
HUP0501069A2 (en) 2006-06-28
PL373848A1 (en) 2005-09-19
TW200301121A (en) 2003-07-01
CA2469670A1 (fr) 2003-06-19
WO2003049740A1 (fr) 2003-06-19
AP2004003058A0 (en) 2004-06-30
AR037771A1 (es) 2004-12-01
KR20040063948A (ko) 2004-07-14
MXPA04004107A (es) 2004-07-23
JP4181502B2 (ja) 2008-11-19
TNSN04111A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
MA27154A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
WO2002046170A8 (fr) Derives d'anilinopyrimidine utilises comme inhibiteurs du chemin de la kinase de n terminal (jnk) et compositions et techniques associees
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
MA31466B1 (fr) Derives de benzimidazole
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
DK0888111T3 (da) Modified-release-dosispræparat med multiple enheder
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
MA26997A1 (fr) Derives de 3-(4-amidopyrrole-2-ylmethylidene)-2-indolinone utilisables comme inhibiteurs de proteine-kinases
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
TR200402704T4 (tr) Yeni fenil-propargileter türevleri
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
CA2312545A1 (fr) Composition pharmaceutique solide thermoformable a liberation controlee
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
CA2191129A1 (fr) Medicaments a base de metronidazole ou d'un melange synergetique de metronidazole et de clindamycine
AU2003281200A1 (en) Immunopotentiating compositions
HK1068136A1 (en) Muscarinic antagonists
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5